Market Report Source

Overview

Introduction
Stress urinary incontinence (SUI) is the most common type of urinary incontinence in women. Up until recently there were no globally developed or widely approved pharmacological treatments for this disorder leaving women with few treatment optionsnon-invasive (e.g. pelvic floor exercises) or invasive (i.e. surgery) non-pharmacological therapy.

Scope
Quantitative treatment data from 419 physicians based in US, Japan, France, Germany, Italy, Spain and the UK; supported by key opinion leader comments
Analysis of epidemiology, presentation and referral patterns, diagnostic assessment, and first- to third-line pharmacological treatments for SUI
Influences on treatment choice and perception of current drug therapies including duloxetine
Evaluation of unmet needs and future outlook including awareness of R&D drug pipeline

Highlights
Despite the high prevalence of SUI among women, a number of factors including embarrassment and poor awareness amongst women act as a barrier to sufferers seeking help for their condition. There is a need for better education and treatment options to improve diagnosis and treatment rates.

Without the widespread availability of an efficacious drug for SUI, many physicians have become reliant on non-pharmacological techniques. Patients and primary care physicians, with little experience of surgery, are less likely to be confident with this treatment option and it is here that pharmacological treatments could gain more support.

The approval of Yentreve (duloxetine) for SUI in the EU has provided another treatment option. However, uptake has not been as rapid as Lilly would have hoped and although this may have been influenced by satisfaction with surgical treatment, to date the available clinical data and experience in clinical practice, has not always been positive.

Reasons to Purchase
Forecast product sales by understanding key aspects of SUI epidemiology, diagnosis and treatment
Gain a better understanding of the challenges facing current and future players in the SUI market
Identify physicians key concerns in SUI including unmet needs and the attributes that physicians believe are desirable for future treatments

Table of Contents

TABLE OF CONTENTS
OVERVIEW
This product has been designed for delivery in a slide pack format (PowerPoint).
Please select the slide pack option from the download menu at the side of the page
Introduction
Scope of this report
Research and analysis highlights
Key reasons to read this report
APPENDIX A
Research methodology
Physician Sample breakdown
Urinary Incontinence and Overactive Bladder Insight Study – Physician Questionnaire
Section One Overview of Urinary Incontinence and overactive Bladder
Epidemiology
Presentation
Diagnosis
Referral pattern
Section Two Stress Urinary Incontinence
Diagnosis and treatment of SUI
Non-pharmacological treatment
Pharmacological treatment for SUI
Section Three Overactive Bladder With Urge Symptoms and/or Incontinence
Diagnosis and treatment of UUI
Pharmacological treatment for UUI
Diagnosis and treatment of ‘dry OAB’
Pharmacological treatment for dry OAB
Section Four Mixed Stress/Urge Urinary Incontinence
Diagnosis and treatment of mixed SUI/UUI
Non-pharmacological treatment
Pharmacological treatment for mixed SUI/UUI
Section Five Interstitial Cystitis
Diagnosis and treatment of IC
Pharmacological treatment for IC
Section Six Drug Profiles
Section A: Drug influences on physicians’ choice
Section B: The general treatment of urinary incontinence and overactive bladder
Contributing experts
US
Japan
Europe
APPENDIX B
About Datamonitor
About Datamonitor Healthcare
About the CNS analysis team
Disclaimer